Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
|Articles|January 29, 2021
Rheumatoid Arthritis Quiz: What Factors Increase Risk of Developing RA?
This week's rheumatoid arthritis quiz was developed by Fotios Koumpouras, MD, Director of Education and Training and Director of the Yale Lupus Program at Yale School of Medicine.
Advertisement
How often is rheumatoid arthritis (RA) seronegative?
A. ~10%
B. ~50%
C. ~1%
D. ~30%
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement